1-3 of 3
Andreas Zimmermann, MD
Close
Sort by
Journal Articles

Efficacy and Safety of Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Extended Follow-up from the GHSG Phase II Nivahl Trial

Paul J Bröckelmann, MD, Helen Goergen, Dipl.-Math., Ulrich Keller, Julia Meissner, MD, Karolin Trautmann, MD, Teresa V Halbsguth, MD, Stephanie Sasse, MD, Martin Sökler, MD, Andrea Kerkhoff, MD, Stephan Mathas, MD, Andreas Hüttmann, MD, Matthias Bormann, MD, Andreas Zimmermann, MD, Michael Fuchs, Bastian von Tresckow, MD, Christian Baues, MD, Andreas Rosenwald, MD, Wolfram Klapper, MD, Carsten Kobe, MD, Peter Borchmann, MD, Andreas Engert, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 6–7.
https://doi.org/10.1182/blood-2020-138413
Published: 2020
Journal Articles

Abscopal Effect of Radiotherapy and Nivolumab in Relapsed or Refractory Hodgkin Lymphoma (AERN): An International Multicenter Single-Arm Two-Stage Phase II GHSG Trial

Paul J Bröckelmann, MD, Annette Plütschow, Richard Greil, MD, Josée M Zijlstra, MD PhD, Timothy Illidge, MD PhD, Alexander Fosså, MD PhD, Julia Meissner, MD, Andreas Zimmermann, MD, Stephan Mathas, MD, Felicitas Thol, MD, Michael Fuchs, MD, Andreas Engert, MD, Christian Baues, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1547.
https://doi.org/10.1182/blood-2019-124351
Published: 2019
Journal Articles

Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL)

Paul J Bröckelmann, MD, Helen Goergen, Dipl.-Math., Ulrich Keller, MD, Julia Meissner, MD, Rainer Ordemann, MD, Teresa V Halbsguth, MD, Stephanie Sasse, MD, Martin Sökler, MD, Andrea Kerkhoff, MD, Stephan Mathas, MD, Andreas Hüttmann, MD, Matthias Bormann, MD, Andreas Zimmermann, MD, Michael Fuchs, MD, Bastian von Tresckow, Christian Baues, MD, Andreas Rosenwald, MD, Wolfram Klapper, Carsten Kobe, Peter Borchmann, MD PhD, Andreas Engert, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 236.
https://doi.org/10.1182/blood-2019-122406
Published: 2019